DIECI, Maria Vittoria
 Distribuzione geografica
Continente #
NA - Nord America 2.607
EU - Europa 1.401
AS - Asia 513
SA - Sud America 12
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
Totale 4.547
Nazione #
US - Stati Uniti d'America 2.594
IE - Irlanda 333
GB - Regno Unito 324
IT - Italia 261
CN - Cina 174
SE - Svezia 146
HK - Hong Kong 137
DE - Germania 122
UA - Ucraina 65
SG - Singapore 49
FI - Finlandia 46
TR - Turchia 39
IN - India 36
BG - Bulgaria 30
ID - Indonesia 23
FR - Francia 21
VN - Vietnam 16
CA - Canada 13
KR - Corea 11
TW - Taiwan 10
CZ - Repubblica Ceca 8
LT - Lituania 8
RU - Federazione Russa 8
ES - Italia 6
IR - Iran 6
BR - Brasile 5
BE - Belgio 4
EG - Egitto 4
CO - Colombia 3
EU - Europa 3
GR - Grecia 3
PL - Polonia 3
AU - Australia 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
IQ - Iraq 2
JP - Giappone 2
LY - Libia 2
MY - Malesia 2
PK - Pakistan 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
AT - Austria 1
HU - Ungheria 1
KE - Kenya 1
LB - Libano 1
LV - Lettonia 1
ME - Montenegro 1
NL - Olanda 1
NO - Norvegia 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
TH - Thailandia 1
Totale 4.547
Città #
Fairfield 391
Dublin 333
Ashburn 237
Woodbridge 234
Southend 229
Chandler 219
Houston 175
Seattle 168
Ann Arbor 135
Hong Kong 135
Cambridge 134
Dearborn 132
Wilmington 118
Jacksonville 114
Nyköping 113
Beijing 55
Modena 46
San Diego 42
Singapore 36
Princeton 34
Helsinki 30
Sofia 30
New York 28
Eugene 25
Jakarta 23
Shanghai 23
Izmir 22
Falls Church 18
Milan 18
London 16
Des Moines 15
Dong Ket 15
Norwalk 15
Redwood City 15
Bologna 14
Bremen 12
Guangzhou 11
Fremont 10
Los Angeles 9
Mumbai 8
Nanjing 8
Ottawa 8
Padova 8
Taipei 8
Catania 7
Rome 7
Boardman 6
Florence 6
Gelsenkirchen 6
Brno 5
Chicago 5
Hyderabad 5
Kilburn 5
Kunming 5
Turin 5
Wuhan 5
Bagnacavallo 4
Bangalore 4
Dortmund 4
Duncan 4
Genoa 4
Nanchang 4
Parma 4
Phoenix 4
San Mateo 4
Shenyang 4
Fulham 3
Gurgaon 3
Hangzhou 3
Hefei 3
Jungnang-gu 3
Legnaro 3
New Bedfont 3
Santiago de Cali 3
Sassuolo 3
Seoul 3
Toronto 3
Trento 3
Wandsworth 3
Assago 2
Augusta 2
Berlin 2
Boston 2
Brussels 2
Calimera 2
Casalgrande 2
Cesena 2
Chania 2
Ferrara 2
Forlì 2
Frankfurt am Main 2
Fuzhou 2
Gangnam-gu 2
Ginosa 2
Hounslow 2
Imola 2
Islington 2
Jinan 2
La Paz 2
Lamezia Terme 2
Totale 3.657
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 278
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 241
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 208
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 193
Immune characterization of breast cancer metastases: prognostic implications. 192
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 191
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 183
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 181
Timing for starting second line therapy in recurrent ovarian cancer. 179
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 173
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 171
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 169
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 166
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 152
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 148
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 142
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 136
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 125
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 123
Tumori ginecologici 116
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 116
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 112
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 107
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 105
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 98
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 87
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. 87
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 87
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 77
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 61
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 57
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 42
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 24
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 24
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 19
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 19
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 15
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 13
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 3
Totale 4.620
Categoria #
all - tutte 18.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.776


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020820 47 39 23 48 93 123 169 78 73 33 63 31
2020/2021962 70 34 69 63 82 109 97 104 66 120 101 47
2021/2022630 29 73 77 19 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/202539 39 0 0 0 0 0 0 0 0 0 0 0
Totale 4.620